Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8188901 | 0.98 | CA1 (0.57) | CA1CA2CA9ALDH1A1IDO1 | |
| SCHEMBL23385506 | 0.94 | HSPB1 (0.66) | CA1CA2CA9ALDH1A1IDO1 | |
| SCHEMBL2011179 | 0.80 | HSPB1 (0.79) | CA1CA2CA9ALDH1A1HSPB1 | |
| SCHEMBL9183872 | 0.80 | HSPB1 (0.79) | CA1CA2CA9ALDH1A1HSPB1 | |
| SCHEMBL11689190 | 0.80 | HSPB1 (0.79) | CA1CA2CA9ALDH1A1HSPB1 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL134332 | 0.80 | HSPB1 (0.79) | CA1CA2CA9ALDH1A1HSPB1 | |
| Hydrazine SCHEMBL27401571 | 0.79 | ALDH1A1 (0.74) | CA1CA2CA9ALDH1A1IDO1 | |
| SCHEMBL27909482 | 0.79 | ALDH1A1 (0.72) | CA1CA2CA9ALDH1A1CES1 | |
| SCHEMBL22567 | 0.79 | ALDH1A1 (0.72) | CA1CA2CA9ALDH1A1CES1 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL8934595 | 0.78 | HSPB1 (0.76) | CA1CA2CA9ALDH1A1HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0312343-B1 | HAIR TREATMENT PRODUCT | UNILEVER PLC (GB) | 1992-06-03 | — | — | EP | claimed |
| EP-0085596-B1 | APPLICATION AS PLANT GROWTH FACTORS OF O-PHENYL HYDROXYL AMINE AND CERTAIN DERIVATIVES THEROF | ROUSSEL-UCLAF (FR) | 1985-03-27 | — | — | EP | claimed |
| JP-60169447-A | — | — | None | — | — | JP | disclosed |
| CN-114423766-B | Pentane derivatives for the treatment of bacterial infections | 丹诺医药(苏州）有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-115505018-B | Fusidic acid derivative with anti-inflammatory activity and preparation method and application thereof | 烟台大学 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023175184-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-11740198-B2 | Formaldehyde detecting sensor and system using the same | NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) | 2023-08-29 | — | — | US | disclosed |
| CN-115505018-A | Fusidic acid derivative with anti-inflammatory activity and preparation method and application thereof | 烟台大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-115109020-A | Spirolactone substituted cyclohexadienone oxime compound and synthesis method thereof | 南方科技大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-114853660-A | Indolinone-substituted cyclohexadienone oxime compound and synthesis method thereof | 南方科技大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-114423766-A | Penicilliane derivatives for the treatment of bacterial infections | 丹诺医药(苏州）有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
| EP-0442172-A1 | Oxime derivatives and Herbicides containing the same as an active ingredient | TEIJIN LIMITED (JP) | 1991-08-21 | — | — | EP | disclosed |
| EP-0433451-A1 | OXIME DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1991-06-26 | — | — | EP | disclosed |
| WO-1990001874-A1 | OXIME DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1990-03-08 | — | — | WO | disclosed |
| JP-S60169447-A | PRODUCTION OF O-ARYL HYDROXYLAMINE | MITSUI PETROCHEM IND LTD | 1985-09-02 | — | — | JP | disclosed |
| US-4451283-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-29 | — | — | US | disclosed |
| WO-1983002545-A1 | APPLICATION AS GROWTH FACTORS OF VEGETABLES OF HYDROXYLAMINE DERIVATIVES | ROUSSEL UCLAF (FR) | 1983-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | CA1 4708/4885CA2 4370/4885CA9 2586/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | CA1 4708/4885CA2 4370/4885CA9 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.